Suppr超能文献

药品的定量微生物风险评估

Quantitative Microbial Risk Assessment of Pharmaceutical Products.

作者信息

Eissa Mostafa Essam

机构信息

HIKMA Pharma for Pharmaceutical Industry, 2 Industrial Zone, 1 Plot, 6 of October City, Giza, Egypt, P.O. 13311

出版信息

PDA J Pharm Sci Technol. 2017 May-Jun;71(3):245-251. doi: 10.5731/pdajpst.2016.007047. Epub 2016 Dec 14.

Abstract

Monitoring of microbiological quality in the pharmaceutical industry is an important criterion that is required to justify safe product release to the drug market. Good manufacturing practice and efficient control on bioburden level of product components are critical parameters that influence the microbiological cleanliness of medicinal products. However, because microbial dispersion through the samples follows Poisson distribution, the rate of detection of microbiologically defective samples lambda (λ) decreases when the number of defective units per batch decreases. When integrating a dose-response model of infection (P) of a specific objectionable microbe with a contamination module, the overall probability of infection from a single batch of pharmaceutical product can be estimated. The combination of P with detectability chance of the test (P) will yield a value that could be used as a quantitative measure of the possibility of passing contaminated batch units of product with a certain load of a specific pathogen and infecting the final consumer without being detected in the firm. The simulation study can be used to assess the risk of contamination and infection from objectionable microorganisms for sterile and non-sterile products. Microbial contamination of pharmaceutical products is a global problem that may lead to infection and possibly death. While reputable pharmaceutical companies strive to deliver microbiologically safe products, it would be helpful to apply an assessment system for the current risk associated with pharmaceutical batches delivered to the drug market. The current methodology may be helpful also in determining the degree of improvement or deterioration on the batch processing flow until reaching the final consumer. Moreover, the present system is flexible and can be applied to other industries such as food, cosmetics, or medical devices manufacturing and processing fields to assess the microbiological risk of the processed and manufactured batch.

摘要

制药行业中微生物质量监测是证明药品能够安全投放市场所需的一项重要标准。良好生产规范以及对产品成分生物负荷水平的有效控制是影响药品微生物洁净度的关键参数。然而,由于样本中的微生物散布遵循泊松分布,当每批中有缺陷单位数量减少时,微生物缺陷样本的检出率λ会降低。将特定有害微生物的感染剂量反应模型(P)与污染模块相结合时,可以估算出单批药品感染的总体概率。P与检测的可检出概率(P)相结合将得出一个值,该值可作为一种定量指标,用于衡量含有一定负荷特定病原体的受污染批次产品通过企业检测并感染最终消费者的可能性。模拟研究可用于评估无菌和非无菌产品受有害微生物污染和感染的风险。药品的微生物污染是一个全球性问题,可能导致感染甚至死亡。虽然知名制药公司努力提供微生物安全的产品,但应用一个评估系统来评估投放药品市场的当前批次药品的相关风险会有所帮助。当前的方法在确定直至到达最终消费者的批次加工流程的改进或恶化程度方面也可能有所帮助。此外,本系统具有灵活性,可应用于其他行业,如食品、化妆品或医疗器械制造及加工领域,以评估加工和制造批次的微生物风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验